Editorial: Abnormal immune regulation and low-grade inflammation in IBS: Does one size fit all

American Journal of Gastroenterology

Volumn 107, Issue 2, 2012, Pages 273-276

  Schmulson, Max ^a   Chey, William D ^b  

^a HOSPITAL GENERAL DE MÉXICO   (Mexico)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; MESSENGER RNA; TOLL LIKE RECEPTOR; BIOLOGICAL MARKER;

ANXIETY; CELL COUNT; COLON MUCOSA; COMORBIDITY; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; ENTEROENDOCRINE CELL; GENE EXPRESSION; HUMAN; IMMUNOREGULATION; IRRITABLE COLON; MENTAL STRESS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; COLON; FEMALE; INTESTINE MUCOSA; MALE; METABOLISM; NOTE;

BIOLOGICAL MARKERS; COLON; FEMALE; HUMANS; INTESTINAL MUCOSA; IRRITABLE BOWEL SYNDROME; MALE;

EID: 84856758488     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2011.427     Document Type: Review

References (27)

1. Ohman L, Simren M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol 2010; 7: 163-73.
2. Chadwick VS, Chen W, Shu D et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002; 122 : 1778-83. (Pubitemid 34651421)
3. Cremon C, Gargano L, Morselli-Labate AM et al. Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am J Gastroenterol 2009; 104: 392-400.
4. Barbara G, Stanghellini V, De Giorgio ret al. Activated mast cells in proximity to colonic nerves correlate withabdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126: 693-702. (Pubitemid 38298317)
5. Gwee KA, Leong YL, Graham C et al. The role of psychological and biological factors in postinfective gut dysfunction. Gut 1999; 44: 400-6. (Pubitemid 29119338)
6. Dunlop SP, Jenkins D, Neal Kret al. Relative importance of enterochromaffi n cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 2003; 125: 1651-9. (Pubitemid 37500429)
7. Gwee KA, Collins SM, Read NW et al. Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome. Gut 2003; 52: 523-6. (Pubitemid 36363405)
8. Akbar A, Yiangou Y, Facer P et al. Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation withabdominal pain. Gut 2008; 57: 923-9. (Pubitemid 351919527)
9. Cenac N, Andrews CN, Holzhausen M et al. Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest 2007; 117 : 636-47. (Pubitemid 46348522)
10. Klooker TK, Braak B, Koopman KE et al. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut 2010; 59: 1213-21.
11. Lee KJ, Kim YB, Kim JH et al. The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors. J Gastroenterol Hepatol 2008; 23: 1689-94.
12. Kraneveld AD, Rijnierse A, Nijkamp FP et al. Neuro-immune interactions in inflammatory bowel disease and irritable bowel syndrome: future therapeutic targets. Eur J Pharmacol 2008; 585: 361-74.
13. Ortiz-Lucas M, Saz-Peiro P, Sebastian-Domingo JJ. Irritable bowel syndrome immune hypothesis. Part two: the role of cytokines. Rev Esp Enferm Dig 2010; 102: 711-7.
14. Liebregts T, Adam B, Bredack C et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007; 132: 913-20. (Pubitemid 46440872)
15. Macsharry J, O ' Mahony L, Fanning A et al. Mucosal cytokine imbalance in irritable bowel syndrome. Scand J Gastroenterol 2008; 43: 1467-76.
16. Gonsalkorale WM, Perrey C, Pravica V et al. Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component? Gut 2003; 52: 91-3. (Pubitemid 36020772)
17. van der Veek PP, van den Berg M, de Kroon YE et al. Role of tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in irritable bowel syndrome. Am J Gastroenterol 2005; 100: 2510-6.
18. Piche T, Barbara G, Aubert P et al. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut 2009; 58: 196-201.
19. Rodriguez-Fandino O, Hernandez-Ruiz J, Schmulson M. From cytokines to toll-like receptors and beyond-current knowledge and future research needs in irritable bowel syndrome. J Neurogastroenterol Motil 2010; 16: 363-73.
20. Brint EK, MacSharry J, Fanning A et al. Differential expression of toll-like receptors in patients with irritable bowel syndrome. Am J Gastroenterol 2011; 106: 329-36.
21. Ohman L, Isaksson S, Lundgren A et al. A controlled study of colonic immune activity and beta7+ blood T lymphocytes in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2005; 3: 980-6. (Pubitemid 41415745)
22. Chang L, Adeyemo M, Karagiannidis I et al. Serum and colonic mucosal immune markers in irritable bowel syndrome. Am J Gastroenterol 2012; 107:262-72 (this issue).
23. Gwee KA. Post-infectious irritable bowel syndrome, an inflammationimmunological model with relevance forother IBS and functional dyspepsia. J Neurogastroenterol Motil 2010; 16: 30-4.
24. Thabane M, Marshall JK. Post-infectious irritable bowel syndrome. World J Gastroenterol 2009; 15: 3591-6.
25. Kassinen A, Krogius-Kurikka L, Makivuokko H et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 2007; 133: 24-33. (Pubitemid 47031125)
26. Scully P, McKernan DP, Keohane J et al. Plasma cytokine profiles in females with irritable bowel syndrome and extra-intestinal co-morbidity. Am J Gastroenterol 2010; 105: 2235-43.
27. Maes M, Song C, Lin A et al. The effects of psychological stress on humans: increased production of pro-inflammatory cytokines and a Th 1-like response in stress-induced anxiety. Cytokine 1998; 10: 313-8. (Pubitemid 28227076)